Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation

Pharmacological Research

Volumn 99, Issue , 2015, Pages 248-257

  Nadeem, Ahmed ^a   Al Harbi, Naif O ^a   Al Harbi, Mohamed M ^a   El Sherbeeny, Ahmed M ^b   Ahmad, Sheikh F ^a   Siddiqui, Nahid ^c   Ansari, Mushtaq A ^a   Zoheir, Khairy M A ^a   Attia, Sabry M ^a   Al Hosaini, Khaled A ^a   Al Sharary, Shakir D ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c AMITY UNIVERSITY   (India)

Author keywords

BET bromodomains; IL 17A; Imiquimod; Psoriasis; receptor C; Retinoic acid receptor related orphan

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; INTERLEUKIN 17; INTERLEUKIN 22; MYELOPEROXIDASE; RETINOIC ACID RECEPTOR RELATED ORPHAN RECEPTOR C; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AMINOQUINOLINE DERIVATIVE; AZEPINE DERIVATIVE; IMIQUIMOD; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RORC PROTEIN, MOUSE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DERMATITIS; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SKIN PROTECTION; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION; SKIN;

AMINOQUINOLINES; ANIMALS; AZEPINES; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-17; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PSORIASIS; SIGNAL TRANSDUCTION; SKIN; TRIAZOLES;

EID: 84951818792     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.06.001     Document Type: Article

References (39)

1. F.O. Nestle, D.H. Kaplan, J. Barker, and N. Psoriasis Engl J Med 361 2009 496 509
2. S.P. Raychaudhuri, and E.M. Farber The prevalence of psoriasis in the world J Eur Acad Dermatol Venereol 15 2001 16 17
3. L. Grine, L. Dejager, C. Libert, and R.E. Vandenbroucke An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17 Cytokine Growth Factor Rev 2014 S1359-6101(14)00137-3
4. J. Kim, and J.G. Krueger The immunopathogenesis of psoriasis Dermatol Clin 33 2015 13 23
5. M.P. Schon, W.H. Boehncke, and N. Psoriasis Engl J Med 352 2005 1899 1912
6. E.F. Wagner, H.B. Schonthaler, J. Guinea-Viniegra, and E. Tschachler Psoriasis: what we have learned from mouse models Nat Rev Rheumatol 6 2010 704 714
7. J. Shi, and C.R. Vakoc The mechanisms behind the therapeutic activity of BET bromodomain inhibition Mol Cell 54 2014 728 736
8. P. Filippakopoulos, and S. Knapp Targeting bromodomains: epigenetic readers of lysine acetylation Nat Rev Drug Discov 13 2014 337 356
9. J. McGrath, and P. Trojer Targeting histone lysine methylation in cancer Pharmacol Ther 2015 10.1016/j.pharmthera.2015.01.002
10. U. Schaefer Pharmacological inhibition of bromodomain-containing proteins in inflammation Cold Spring Harb Perspect Biol 6 2014 a018671
11. A.C. Belkina, B.S. Nikolajczyk, and G.V. Denis BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses J Immunol 190 2013 3670 3678
12. C.H. Chan, C. Fang, Y. Qiao, A. Yarilina, R.K. Prinjha, and L.B. Ivashkiv BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes Eur J Immunol 45 2015 287 297
13. D.A. Mele, A. Salmeron, S. Ghosh, H.R. Huang, B.M. Bryant, and J.M. Lora BET bromodomain inhibition suppresses TH17-mediated pathology J Exp Med 210 2013 2181 2190
14. H.S. Bandukwala, J. Gagnon, S. Togher, J.A. Greenbaum, E.D. Lamperti, N.J. Parr, and et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors Proc Natl Acad Sci U S A 109 2012 14532 14537
15. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, and et al. Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
16. J.E. Delmore, G.C. Issa, M.E. Lemieux, P.B. Rahl, J. Shi, H.M. Jacobs, and et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 146 2011 904 917
17. L. van der Fits, S. Mourits, J.S. Voerman, M. Kant, L. Boon, J.D. Laman, and et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis J Immunol 182 2009 5836 5845
18. S. Pantelyushin, S. Haak, B. Ingold, P. Kulig, F.L. Heppner, A.A. Navarini, and et al. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice J Clin Invest 122 2012 2252 2256
19. L. Tortola, E. Rosenwald, B. Abel, H. Blumberg, M. Schäfer, A.J. Coyle, and et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk J Clin Invest 122 2012 3965 3976
20. E. Fitch, E. Harper, I. Skorcheva, S.E. Kurtz, and A. Blauvelt Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines Curr Rheumatol Rep 9 2007 461 467
21. A.S. Lønnberg, C. Zachariae, and L. Skov Targeting of interleukin-17 in the treatment of psoriasis Clin Cosmet Investig Dermatol 7 2014 251 259
22. A.B. Van Belle, M. de Heusch, M.M. Lemaire, E. Hendrickx, G. Warnier, K. Dunussi-Joannopoulos, and et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice J Immunol 188 2012 462 469
23. K.A. Papp, C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, G. Kricorian, and et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N Engl J Med 366 2012 1181 1189
24. S.F. Ahmad, M.A. Ansari, K.M. Zoheir, S.A. Bakheet, H.M. Korashy, A. Nadeem, and et al. Regulation of TNF-α and NF-κB activation through the JAK/STAT signaling pathway downstream of histamine 4 receptor in a rat model of LPS-induced joint inflammation Immunobiology 2015 10.1016/j.imbio.2015.01.008
25. A. Nadeem, D.S. Ponnoth, H.R. Ansari, T.P. Batchelor, R.D. Dey, C. Ledent, and S.J. Mustafa A2A adenosine receptor deficiency leads to impaired tracheal relaxation via NADPH oxidase pathway in allergic mice J Pharmacol Exp Ther 330 2009 99 108
26. A. Nadeem, N.O. Alharbi, H. Vliagoftis, M. Tyagi, S.F. Ahmad, and M.M. Sayed-Ahmed Protease activated receptor-2 mediated dual oxidase-2 upregulation is involved in enhanced airway reactivity and inflammation in a mouse model of allergic asthma Immunology 2015 10.1111/imm.12453
27. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method Methods 25 2001 402 408
28. P.P. Bradley, D.A. Priebat, R.D. Christensen, and G. Rothstein Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker J Invest Dermatol 78 1982 206 209
29. R. Yoshiki, K. Kabashima, T. Honda, S. Nakamizo, Y. Sawada, K. Sugita, and et al. IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells J Invest Dermatol 134 2014 1912 1921
30. S. Kagami, H.L. Rizzo, J.J. Lee, Y. Koguchi, and A. Blauvelt Circulating Th17, Th22, and Th1 cells are increased in psoriasis J Invest Dermatol 130 2010 1373 1383
31. C. Johansen, P.A. Usher, R.B. Kjellerup, D. Lundsgaard, L. Iversen, and K. Kragballe Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin Br J Dermatol 160 2009 319 324
32. K. Nakajima, T. Kanda, M. Takaishi, T. Shiga, K. Miyoshi, H. Nakajima, and et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model J Immunol 186 2011 4481 4489
33. I.I. Ivanov, B.S. McKenzie, L. Zhou, C.E. Tadokoro, A. Lepelley, J.J. Lafaille, and et al. The orphan nuclear receptor RORgamma-t directs the differentiation program of proinflammatory IL-17+ T helper cells Cell 126 2006 1121 1133
34. J. Yang, M.S. Sundrud, J. Skepner, and T. Yamagata Targeting Th17 cells in autoimmune diseases Trends Pharmacol Sci 35 2014 493 500
35. M.R. Chang, B. Lyda, T.M. Kamenecka, and P.R. Griffin Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor γ is therapeutic in the collagen-induced arthritis experimental model Arthritis Rheumatol 66 2014 579 588
36. S. Ano, Y. Morishima, Y. Ishii, K. Yoh, Y. Yageta, S. Ohtsuka, and et al. Transcription factors GATA-3 and RORγt are important for determining the phenotype of allergic airway inflammation in a murine model of asthma J Immunol 190 2013 1056 1065
37. C.E. Sutton, L.A. Mielke, and K.H. Mills IL-17-producing γδ T cells and innate lymphoid cells Eur J Immunol 42 2012 2221 2231
38. F. Isono, S. Fujita-Sato, and S. Ito Inhibiting RORγt/Th17 axis for autoimmune disorders Drug Discov Today 19 2014 1205 1211
39. D.R. Littman, and A.Y. Rudensky Th17 and regulatory T cells in mediating and restraining inflammation Cell 140 2010 845 858